NeuroPace Inc (NPCE) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, NeuroPace reported revenue of $100.0M, up 25.1% from $79.9M the year before. Net income was -$21.5M (a -21.5% net margin), or -$0.66 per diluted share. Gross margin was 77.2% and operating margin was -16.3%. Operating activities generated -$11.0M of cash, leaving -$11.3M of free cash flow. At fiscal year end, NeuroPace held $105.6M in total assets against $86.5M in total liabilities, including $21.7M of cash and equivalents.
Open the full interactive NeuroPace financials → Quarterly statements, key ratios, valuation history and price charts.
NeuroPace Key Stats
| Share Price | $12.68 |
|---|---|
| Market Cap | $432.4M |
| Revenue YoY Growth | +25.1% |
| 52-Week Range | $9.40 – $19.29 |
| Shares Outstanding | 34.1 million (basic, 2026 Q2) |
NeuroPace Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $45.2M | $45.5M | $65.4M | $79.9M | $100.0M |
| Cost of Goods Sold | $11.7M | $13.0M | $17.3M | $20.8M | $22.8M |
| Gross Profit | $33.4M | $32.5M | $48.1M | $59.1M | $77.2M |
| Operating Income | -$23.7M | -$40.8M | -$27.2M | -$21.7M | -$16.3M |
| Pre-Tax Income | -$36.1M | -$47.1M | -$33.0M | -$27.1M | -$21.5M |
| Income Tax | — | — | — | — | $0 |
| Net Income | -$36.1M | -$47.1M | -$33.0M | -$27.1M | -$21.5M |
| Diluted EPS | -$2.17 | -$1.91 | -$1.27 | -$0.93 | -$0.66 |
NeuroPace Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $27.4M | $26.6M | $22.1M | $22.8M |
| Net Income | -$3.5M | -$2.7M | -$6.7M | -$6.2M |
| Diluted EPS | -$0.11 | -$0.08 | -$0.20 | -$0.18 |
NeuroPace Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $19.2M | $6.6M | $18.1M | $13.4M | $21.7M |
| Current Assets | $132.8M | $97.7M | $92.7M | $81.3M | $94.1M |
| Total Assets | $133.6M | $114.1M | $107.7M | $94.6M | $105.6M |
| Current Liabilities | $9.3M | $11.0M | $16.2M | $15.2M | $17.8M |
| Total Long-Term Debt | $49.8M | $52.9M | $57.0M | $59.5M | $58.9M |
| Total Liabilities | $60.1M | $79.3M | $87.0M | $86.6M | $86.5M |
| Shareholders' Equity | $73.5M | $34.8M | $20.7M | $8.0M | $19.0M |
NeuroPace Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$24.6M | -$36.9M | -$19.7M | -$17.9M | -$11.0M |
| Cash From Investing | -$85.4M | $23.8M | $23.0M | $9.0M | -$332,000 |
| Cash From Financing | $102.5M | $490,000 | $8.1M | $4.3M | $19.6M |
| Free Cash Flow | -$25.0M | -$37.5M | -$19.9M | -$18.2M | -$11.3M |
Figures from NeuroPace's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full NeuroPace financials page for every line item.
NeuroPace Company Profile
| Ticker | NPCE |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Mountain View, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001528287 |
Frequently Asked Questions
What was NeuroPace's revenue in fiscal 2025?
NeuroPace (NPCE) reported revenue of $100.0M for fiscal 2025.
What is NeuroPace's annual revenue history?
NeuroPace's annual revenue by fiscal year: 2021: $45.2M; 2022: $45.5M; 2023: $65.4M; 2024: $79.9M; 2025: $100.0M.
What was NeuroPace's net income in fiscal 2025?
NeuroPace reported net income of -$21.5M for fiscal 2025.
What was NeuroPace's earnings per share (EPS) in fiscal 2025?
NeuroPace's diluted EPS was -$0.66 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did NeuroPace generate in fiscal 2025?
NeuroPace generated -$11.3M of free cash flow in fiscal 2025.
What was NeuroPace's revenue last quarter?
In its most recent reported quarter (2026 Q2), NeuroPace reported revenue of $22.8M.
How much debt does NeuroPace have?
NeuroPace reported $58.9M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of NeuroPace are outstanding?
NeuroPace reported a weighted average of 34.1 million basic shares outstanding in 2026 Q2.
What is NeuroPace's market cap?
Based on its latest closing price, NeuroPace (NPCE) has a market capitalization of about $432.4M.
When does NeuroPace's fiscal year end?
NeuroPace's fiscal year end, as registered with the SEC, is December 31.
Where is NeuroPace headquartered?
NeuroPace lists its business address in Mountain View, California in its SEC filings.